Marché du diagnostic du cancer du foie – Analyse des tendances et de la croissance | Année de prévision 2031

  • Report Code : TIPRE00003017
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 181
Buy Now

Le marché du diagnostic du cancer du foie devrait atteindre 15 951,77 millions de dollars US d'ici 2028 contre 9 323,14 millions de dollars US en 2021. Le marché devrait croître à un TCAC de 8,0 % entre 2021 et 2028.



Le cancer du foie prend naissance dans les cellules du foie. Plusieurs types de cancer peuvent se former dans le foie. Le carcinome hépatocellulaire est considéré comme le cancer du foie le plus courant et commence dans l'hépatocyte. Selon l'American Society of Clinical Oncology (ASCO), environ 80 % des cancers primitifs du foie chez l'adulte sont des carcinomes hépatocellulaires. D'autres types de cancer du foie comprennent l'hépatoblastome et le cholangiocarcinome intrahépatique. Ceux-ci sont considérés comme moins fréquents. Le diagnostic du cancer du foie comprend des techniques utilisées pour l'identification et la confirmation du cancer du foie.



Aperçus stratégiques



La croissance du marché du diagnostic du cancer du foie est attribuée à la prévalence croissante du cancer du foie et l'augmentation des investissements en R&D dans le développement de nouveaux tests de diagnostic. D'autre part, le coût élevé des solutions de diagnostic du cancer du foie technologiquement avancées entrave la croissance du marché.



Régions lucratives sur le marché du diagnostic du cancer du foie


< CONSEIL>

Perspectives du marché Augmentation des investissements en R&D dans le développement de nouveaux tests de diagnostic



La capacité de diagnostiquer avec précision la progression du cancer du foie est essentielle pour sélectionner l'option de traitement appropriée. De plus, diverses entreprises et organisations ont pris d'énormes initiatives pour développer et mettre en œuvre des solutions innovantes pour l'identification précoce de cette maladie en réponse à la demande croissante. Par exemple, en mars 2020, le score Elecsys GALAD de Roche Holding AG a reçu le statut de dispositif révolutionnaire de la Food and Drug Administration des États-Unis pour la détection précoce d'une forme avancée de cancer du foie. La calculatrice du fabricant de médicaments suisse combine des facteurs tels que l'âge, le sexe et les résultats des biomarqueurs pour détecter le carcinome hépatocellulaire à un stade précoce, qui est la forme la plus courante de cancer du foie. De plus, le score Elecsys GALAD est conçu pour aider les cliniciens en leur fournissant un diagnostic rapide et précis du carcinome hépatocellulaire. Les dépenses de recherche et développement (R&D) en 2021 étaient de 14,65 milliards de dollars américains et en 2020, elles étaient de 13,17 milliards de dollars américains. Les dépenses de R&D ont augmenté de 14 % sur une base centrale, chez F. Hoffmann-La Roche Ltd, principalement en raison d'investissements de stade avancé dans l'oncologie, l'ophtalmologie et les soins de santé personnalisés. En 2021, l'investissement en R&D dans la division de diagnostic était de 1 878,92 millions de dollars US. De même, en novembre 2019, EXACT Sciences Corporation a reçu la désignation révolutionnaire de la Food and Drug Administrations (FDA) pour son test sanguin de détection précoce du cancer du foie. De plus, en juin 2020, les scientifiques des National Institutes of Health (NIH) ont développé des tests sanguins pour aider à améliorer le dépistage du cancer du foie, dirigés par des chercheurs du National Cancer Institute (NCI). De plus, en juin 2019, CancerSEEK, un test de biopsie liquide, a été conçu par des chercheurs de l'Université Johns Hopkins. Le test a été conçu pour diagnostiquer plusieurs cancers, notamment ceux de l'estomac, du foie, des ovaires et de l'œsophage, à un stade précoce, facilitant ainsi un traitement précoce. Par conséquent, les investissements croissants en R&D et le développement de tests de diagnostic pour la détection du cancer du foie stimulent le marché du diagnostic du cancer du foie.



Type-Based Insights


< CONSEIL>

Le marché mondial du diagnostic du cancer du foie, basé sur le type, est segmenté en tests de laboratoire, endoscopie, imagerie, biopsie et autres. Le marché du segment des tests de laboratoire est encore segmenté en tests sanguins et biomarqueurs. Le segment des tests de laboratoire détenait la plus grande part du marché en 2021. Cependant, le segment de l'imagerie devrait enregistrer un TCAC de 8,5 % sur le marché au cours de la période de prévision.



Marché du diagnostic du cancer du foie, par type – 2021 et 2028



Informations basées sur l'utilisateur final


< CONSEIL>

Sur la base de l'utilisateur final, le marché mondial du diagnostic du cancer du foie est segmenté en hôpitaux et laboratoires de diagnostic, instituts universitaires et de recherche et laboratoires CRO. Le segment des hôpitaux et des laboratoires de diagnostic détenait la plus grande part du marché en 2021, car les hôpitaux fournissent des établissements de santé grâce à des équipements scientifiques spécialisés. Une équipe de personnel qualifié est chargée de traiter, d'enquêter et de résoudre les problèmes associés à la science médicale moderne à l'hôpital. Diverses équipes de recherche médicale travaillent constamment à l'introduction de technologies innovantes liées aux méthodes de diagnostic et à d'autres activités dans le domaine médical. Les patients préfèrent généralement l'hôpital pour suivre un traitement contre le cancer du foie en raison de la disponibilité d'options de traitement avancées. Les hôpitaux sont le lieu de soins pour les patients. De plus, le même segment devrait enregistrer un TCAC de 8,5 % sur le marché au cours de la période de prévision.



Les lancements et les approbations de produits sont des stratégies couramment adoptées par les entreprises pour étendre leur empreinte mondiale et des portefeuilles de produits pour dominer la part de marché du diagnostic du cancer du foie. De plus, les acteurs du marché misent sur la stratégie de partenariat pour élargir leur clientèle, ce qui, à son tour, leur permet de maintenir leur marque à l'échelle mondiale. La part de marché du diagnostic du cancer du foie devrait prospérer avec le développement de nouveaux produits innovants par les acteurs du marché.



Profils des entreprises



    < CONSEIL>
  1. Abbott

  2. BioMérieux SA

  3. F. HOFFMANN-LA ROCHE LTD

  4. Illumina, Inc.

  5. Koninklijke Philips NV

  6. QIAGEN

  7. Siemens Healthineers AG

  8. THERMO FISHER SCIENTIFIC INC.

  9. GE Healthcare

  10. Perspectum
  11. Helio, Inc.



Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are liver cancer diagnostics?

The abnormal proliferation of cells in the body is referred to as cancer. Cancer of the liver starts in the cells of the liver. The liver can develop a variety of cancers. Hepatocellular carcinoma is the most prevalent type of liver cancer, and it starts in the hepatocyte. Some liver cancers can be detected through screening in persons who are at high risk but do not have symptoms, but most liver cancers are discovered when they produce symptoms. To detect liver disease, a series of blood tests known as liver function tests and imaging studies are employed.

What are the driving factors for the liver cancer diagnostics market across the globe?

Key factors that are driving the growth of this market are the rising prevalence of liver cancer and rising R&D investments for the development of novel diagnostic testing are expected to boost the market growth for liver cancer diagnostics over the years.

What is the market CAGR value of the liver cancer diagnostics market during the forecast period?

The CAGR value of the liver cancer diagnostics market during the forecasted period of 2021-2028 is 8.0%.

Which type led the liver cancer diagnostics market?

The laboratory tests segment held the largest share of the market in the global liver cancer diagnostics market and held the largest market share of 39.61% in 2021.

Which end user held the largest share in the liver cancer diagnostics market?

The hospitals and diagnostic laboratories segment dominated the global liver cancer diagnostics market and accounted for the largest market share of 48.56% in 2021.

Who are the key players in the Liver Cancer Diagnostics market?

The liver cancer diagnostics market majorly consists of players such as Abbott; bioMerieux SA; F. HOFFMANN-LA ROCHE LTD.; Illumina, Inc.; Koninklijke Philips N.V.; QIAGEN; Siemens Healthineers AG; THERMO FISHER SCIENTIFIC INC.; GE Healthcare; Perspectum; Helio, Inc amongst others.

Which are the top companies that hold the market share in liver cancer diagnostics market?

Koninklijke Philips N.V. and Siemens Healthineers AG are the top two companies that hold huge market shares in the liver cancer diagnostics market.

Which region is expected to witness significant demand for the liver cancer diagnostics market in the coming years?

The North America region secures a substantial share of the global liver cancer diagnostics market. The growth of the market in the region is attributed by the rising prevalence of liver cancer. In North America, the US is the largest market for liver cancer diagnostics. The growth of this market is primarily driven by the growing prevalence of liver cancer diseases, technological advancements and developments in the US are going to accelerate the growth of this market in this country.

What is the COVID 19 impact on the Liver Cancer Diagnostics market in the coming years?

The coronavirus disease 2019 (COVID-19) pandemic has caused unprecedented problems to healthcare systems, and patients with liver cancer (LC) may have been particularly affected. COVID-19 may aggravate pre-existing chronic liver damage in HCC patients, complicating cancer treatment. Cancer patients, especially those who have just completed treatment, are at a higher risk of infection and have a poorer prognosis. The first wave of the COVID-19 epidemic had a huge influence on liver cancer patients' normal care. Patients' outcomes may have been considerably harmed as a result of changes to screening, diagnostic, and treatment algorithms. The benefits and drawbacks of the tactics used will be reported through ongoing data collecting and future analysis, assisting future decision-making. However, in the long run, as the vaccination schedule is established and the transmission rate decreases, healthcare systems will return to normal and is expected to experience increased demand for liver cancer diagnostics.

The List of Companies - Liver Cancer Diagnostic Market

  1. Abbott
  2. BioMerieux SA
  3. F. HOFFMANN-LA ROCHE LTD
  4. Illumina, Inc.
  5. Koninklijke Philips N.V
  6. QIAGEN
  7. Siemens Healthineers AG
  8. THERMO FISHER SCIENTIFIC INC.
  9. GE Healthcare
  10. Perspectum
  11. Helio, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports